Despite preclinical and clinical studies that have demonstrated PARPi-mediated immunosuppression via PD-L1 induction and complementary restoration of PARPi sensitivity via PD-L1 inhibition, with the added possibility of enhanced anti-tumor immunity, many unanswered questions remain regarding the potential benefit of combined targeted therapies and ICIs in TNBC. The gene discussed is CD274; the disease is neoplasm.